Regulatory T cells (Tregs) are critical for proper control of the immune response and play a clear role in regulation of autoimmune disease. Further highlighting their importance, Tregs provide an antigen specific therapy that is currently being evaluated in preclinical and clinical trials. Although they are of unquestioned value, it is difficult to assess Treg specificity for antigen. In fact, many experimental protocols make use of non-specific TCR stimuli such as anti-CD3/anti-CD28 for their activation, and typical assessments of specificity such as peptide: MHC Class II tetramers and functional readouts are not especially effective when applied to Tregs. As TCR specificity and affinity are crucial to any T cell functional response, we need to understand what affinity range works best for optimal Treg use as well as for their differentiation. Our lab is in a unique position to examine questions on TCR specificity and affinity because we have developed a novel assay system based on two dimensional (2D) micropipette technology that provides the most sensitive means currently available to assess these parameters. The prevalent view of thymic derived Tregs (tTreg) in terms of affinity is that their repertoires are comprised of the highest affinity TCRs that escaped negative selection; however, our preliminary data has identified a range of affinities of tTregs specific for myelin oligodendrocyte glycoprotein (MOG). Instead of driving thymocyte negative selection, MOG supports development of thymic derived MOG specific Tregs. We propose that these Tregs will be of therapeutic use and based on our preliminary studies, propose the following two aims to track Treg specificity, location, kinetics, stability, and potency during chronic and relapsing/remitting demyelinating disease.
Aim 1 : To define MOG-specific Treg affinity and frequency during demyelinating disease- Aim 2: To determine Treg specificity and lineage stability for MOG-
Regulatory T cells control the extent of adaptive immune responses, are crucial for the prevention of autoimmune diseases, and play a defined role in human health. Our studies will address a currently unmet need by determining Treg affinity and specificity for myelin.
|Baker, Brian M; Evavold, Brian D (2017) MHC Bias by T Cell Receptors: Genetic Evidence for MHC and TCR Coevolution. Trends Immunol 38:2-4|
|Bally, Alexander P R; Tang, Yan; Lee, Joshua T et al. (2017) Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory. J Immunol 198:205-217|
|Blanchfield, Lori; Sabatino Jr, Joseph J; Lawrence, Laurel et al. (2017) NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease. J Immunol 199:2680-2691|
|Martinez, Ryan J; Andargachew, Rakieb; Martinez, Hunter A et al. (2016) Low-affinity CD4+ T cells are major responders in the primary immune response. Nat Commun 7:13848|
|Martinez, Ryan J; Morris, Anna B; Neeld, Dennis K et al. (2016) Targeted loss of SHP1 in murine thymocytes dampens TCR signaling late in selection. Eur J Immunol 46:2103-10|
|Hood, Jennifer D; Zarnitsyna, Veronika I; Zhu, Cheng et al. (2015) Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease. J Immunol 195:4162-70|
|Martinez, Ryan J; Evavold, Brian D (2015) Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response. Front Immunol 6:468|